Toll-like receptor ligands energize peptide vaccines through multiple paths

Research output: Contribution to journalReview article

42 Citations (Scopus)

Abstract

The potential of vaccines for cancer therapy or prevention has yet to be realized. Recently, we showed that using an immunologic adjuvant composed of a Toll-like receptor (TLR) ligand can increase the production of antitumor CTLs produced by a peptide vaccine in a mouse model of breast cancer. By increasing the cross talk between the innate and adaptive immune systems, TLR ligands can drive expansion and memory of CTLs that can destroy cancer cells.

Original languageEnglish (US)
Pages (from-to)7945-7947
Number of pages3
JournalCancer Research
Volume67
Issue number17
DOIs
StatePublished - Sep 1 2007

Fingerprint

Subunit Vaccines
Toll-Like Receptors
Ligands
Immunologic Adjuvants
Active Immunotherapy
Immune System
Breast Neoplasms
Neoplasms
Drive

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Toll-like receptor ligands energize peptide vaccines through multiple paths. / Celis, Esteban.

In: Cancer Research, Vol. 67, No. 17, 01.09.2007, p. 7945-7947.

Research output: Contribution to journalReview article

@article{4e78369d2e64484cadc22e2bb0732565,
title = "Toll-like receptor ligands energize peptide vaccines through multiple paths",
abstract = "The potential of vaccines for cancer therapy or prevention has yet to be realized. Recently, we showed that using an immunologic adjuvant composed of a Toll-like receptor (TLR) ligand can increase the production of antitumor CTLs produced by a peptide vaccine in a mouse model of breast cancer. By increasing the cross talk between the innate and adaptive immune systems, TLR ligands can drive expansion and memory of CTLs that can destroy cancer cells.",
author = "Esteban Celis",
year = "2007",
month = "9",
day = "1",
doi = "10.1158/0008-5472.CAN-07-1652",
language = "English (US)",
volume = "67",
pages = "7945--7947",
journal = "Cancer Research",
issn = "0008-5472",
publisher = "American Association for Cancer Research Inc.",
number = "17",

}

TY - JOUR

T1 - Toll-like receptor ligands energize peptide vaccines through multiple paths

AU - Celis, Esteban

PY - 2007/9/1

Y1 - 2007/9/1

N2 - The potential of vaccines for cancer therapy or prevention has yet to be realized. Recently, we showed that using an immunologic adjuvant composed of a Toll-like receptor (TLR) ligand can increase the production of antitumor CTLs produced by a peptide vaccine in a mouse model of breast cancer. By increasing the cross talk between the innate and adaptive immune systems, TLR ligands can drive expansion and memory of CTLs that can destroy cancer cells.

AB - The potential of vaccines for cancer therapy or prevention has yet to be realized. Recently, we showed that using an immunologic adjuvant composed of a Toll-like receptor (TLR) ligand can increase the production of antitumor CTLs produced by a peptide vaccine in a mouse model of breast cancer. By increasing the cross talk between the innate and adaptive immune systems, TLR ligands can drive expansion and memory of CTLs that can destroy cancer cells.

UR - http://www.scopus.com/inward/record.url?scp=34548569047&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34548569047&partnerID=8YFLogxK

U2 - 10.1158/0008-5472.CAN-07-1652

DO - 10.1158/0008-5472.CAN-07-1652

M3 - Review article

VL - 67

SP - 7945

EP - 7947

JO - Cancer Research

JF - Cancer Research

SN - 0008-5472

IS - 17

ER -